Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Business Wire

25 Jun 2026, 15:51 UTC · 1h ago

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

What the story claims

2 claims · each scored for market impact

What matters in this story

1
The FDA has cleared the Investigational New Drug (IND) application for a Phase 2 trial. — FDA clearance for a Phase 2 trial is a major clinical milestone that validates the drug's safety and potential efficacy, significantly reducing binary risk.
+0.60
2
IBX secured firm commitments for AU$3.75M (US$2.59M) in new capital. — New funding provides the necessary liquidity to execute the trial, though the amount is relatively small compared to typical late-stage clinical costs.
+0.30

Which stocks this story touches

How each ticker is affected

IBX+0.80
The company secured new capital and received FDA clearance for a Phase 2 trial.

Read original · https://www.businesswire.com/news/home/20260625573810/en/Imagion-Biosystems-Secures-AU3.75M-in-Capital-Raise-Following-FDA-Clearance-of-Phase-2-Clinical-Trial/

6 related stories

PRNewsWire
5h ago
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
- biotech
- fda
Read

Imagion Biosystems Secures… — IBX +0.80 | NewsImpactScreener

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

What matters in this story

How each ticker is affected

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

What matters in this story

How each ticker is affected

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

ImmuPharma appoints Bachem to manufacture key ingredient for diabetes drug

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

What matters in this story

How each ticker is affected

Next reads from the same story arc

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

What matters in this story

How each ticker is affected

Next reads from the same story arc

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

ImmuPharma appoints Bachem to manufacture key ingredient for diabetes drug

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman